# Myris Therapeutics

> Myris Therapeutics is a Pittsburgh-based precision oncology company building the next generation of antibody drug conjugates (ADCs). Formerly BioHybrid Solutions, Myris uses proprietary polymer chemistry rooted in Carnegie Mellon's ATRP (atom transfer radical polymerization) technology to grow polymer bottlebrushes on antibodies, achieving ultra-high drug-to-antibody ratios (DAR) of 50-300 - roughly 10 to 100 times higher than conventional ADCs. That capability opens up new chemical space for cancer payloads that were previously unusable, aiming to deliver more potent, precisely targeted therapies.

- **Founded:** 2025
- **Headquarters:** Pittsburgh (Sharpsburg), Pennsylvania, United States
- **Founders:** Krzysztof Matyjaszewski (Co-Founder & Board Director (ATRP pioneer, Carnegie Mellon)), Tonia Simakova (Co-Founder, leads discovery research), Alan Russell (Co-Founder & Chair of Scientific Advisory Board)
- **Team size:** ~25 employees
- **Products:** Ultra-High DAR ADC Platform, ATRP 'Growing From' Bioconjugation, Oncology Preclinical Pipeline, Microbial Enzyme Therapeutics (partnered)
- **Notable:** Emerged from stealth on February 20, 2025 as a rebrand of BioHybrid Solutions., Developed a platform capable of ultra-high DAR ADCs (DAR 50-300), 10-100x conventional standards., Secured Department of Defense funding for its lead program and nominated a development candidate.

## Products & services

- **Ultra-High DAR ADC Platform** — Proprietary polymer-chemistry platform that grows ATRP polymer bottlebrushes on antibodies to attach 50-300 drug payloads per antibody (DAR50-300), roughly 10-100x conventional standards.
- **ATRP 'Growing From' Bioconjugation** — Atom transfer radical polymerization technique that builds polymer scaffolds directly on the antibody for high-density, controllable payload attachment.
- **Oncology Preclinical Pipeline** — Lead cancer program with a nominated development candidate, funded in part by the U.S. Department of Defense.
- **Microbial Enzyme Therapeutics (partnered)** — Enzyme-based bioconjugate drug candidates for indications such as gout and nerve agent poisoning, carried over from the BioHybrid Solutions heritage.

## Achievements

- Emerged from stealth on February 20, 2025 as a rebrand of BioHybrid Solutions.
- Developed a platform capable of ultra-high DAR ADCs (DAR 50-300), 10-100x conventional standards.
- Secured Department of Defense funding for its lead program and nominated a development candidate.
- Recruited a leadership and advisory bench spanning Amgen, Dana-Farber/Harvard, MD Anderson, ImmunoGen, and Eli Lilly.
- Built on 30+ years and 1,000+ publications of ATRP research from Carnegie Mellon University.
- Presented first public ADC capability data at AACR 2025 in Chicago (April 25-30, 2025).

## Latest updates

- **2025-02** — Myris Therapeutics emerged from stealth, rebranding from BioHybrid Solutions to focus on ultra-high DAR ADCs for cancer.
- **2025-04** — First public presentation of Myris' ADC capabilities at the AACR Annual Meeting in Chicago (April 25-30, 2025).
- **2024** — Laura Benjamin, PhD stepped in as CEO to lead the company's strategic pivot to oncology.
- **2023-12** — Reported seed-stage funding activity; Laura Benjamin joined the board in 2023.

## Links

- Website: https://myristx.com
- LinkedIn: http://www.linkedin.com/company/myristherapeutics

---

Profile page: https://yespress.io/myris-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-03